Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.62 |
| ▸ | HTR7 | P34969 | 5/20 | 0.59 |
| ▸ | HTR1A | P08908 | 7/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | HTR6 | P50406 | 4/20 | 0.56 |
| ▸ | HTR3A | P46098 | 4/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR5A | P47898 | 2/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.56 |
| ▸ | HTR3B | O95264 | 2/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | NCF1 | P14598 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2414711 | 1.00 | ADRB1 (0.62) | ADRB1HTR7HTR1ASLC6A2SLC6A4 | |
| SCHEMBL29448034 | 1.00 | ADRB1 (0.62) | ADRB1HTR7HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL1239646 | 0.98 | ADRB1 (0.60) | ADRB1HTR7HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL29882262 | 0.98 | ADRB1 (0.60) | ADRB1HTR7HTR1ASLC6A2SLC6A4 | |
| SCHEMBL19187683 | 0.93 | ADRB1 (0.55) | ADRB1HTR7HTR1ASLC6A2SLC6A4 | |
| SCHEMBL15834279 | 0.84 | ADRB1 (0.75) | ADRB1HTR7HTR1ASLC6A2SLC6A4 | |
| SCHEMBL30839785 | 0.84 | HTR1A (0.58) | ADRB1HTR7HTR1ASLC6A2SLC6A4 | |
| SCHEMBL1441614 | 0.84 | HTR1A (0.58) | ADRB1HTR7HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL7241183 | 0.82 | HTR1A (0.57) | ADRB1HTR7HTR1ASLC6A2SLC6A4 | |
| SCHEMBL5370353 | 0.81 | HTR6 (0.64) | ADRB1HTR7HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118396080-A | Distributed machine learning privacy protection method and system based on homomorphic encryption and signature algorithm | 东南大学 | 2024-07-26 | — | — | CN | claimed |
| CN-116227738-B | Method and system for predicting traffic interval of power grid customer service | 广东电网有限责任公司 | 2023-12-08 | — | — | CN | claimed |
| CN-116680816-B | Method, device, equipment and medium for correcting hole-making normal vector of aircraft component | 成都飞机工业（集团）有限责任公司 | 2023-11-10 | — | — | CN | claimed |
| CN-116680816-A | Method, device, equipment and medium for correcting hole-making normal vector of aircraft component | 成都飞机工业（集团）有限责任公司 | 2023-09-01 | — | — | CN | claimed |
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | CELLGENTEK CO., LTD. (KR) | 2023-05-18 | — | — | US | claimed |
| CN-108473451-B | Synthesis of 1- [2- (2, 4-dimethyl-phenylsulfanyl) -phenyl ] piperazine | H.隆德贝克有限公司 | 2022-07-15 | — | — | CN | claimed |
| EP-4019495-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | Cellgentek Co., Ltd (KR) | 2022-06-29 | — | — | EP | claimed |
| CN-108690216-B | Base material for liquid filter | 帝人株式会社 | 2022-06-21 | — | — | CN | claimed |
| CN-113343419-B | Design and evaluation method for line width of mutual injection locking light source | 成都飞机工业（集团）有限责任公司 | 2022-06-14 | — | — | CN | claimed |
| CN-113103211-B | Feedforward control method and device for parallel processing robot | 清华大学 | 2022-06-14 | — | — | CN | claimed |
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | SEQUELLA, INC. | 2005-05-26 | — | — | US | claimed |
| WO-2005034857-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA, INC. (US) | 2005-04-21 | — | — | WO | claimed |
| CN-1186332-C | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2005-01-26 | — | — | CN | claimed |
| EP-1204677-A2 | CYCLOHEXAPEPTIDE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2002-05-15 | — | — | EP | claimed |
| CN-1337953-A | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2002-02-27 | — | — | CN | claimed |
| WO-2001007468-A2 | NOVEL CYCLOHEXAPEPTIDE COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-02-01 | — | — | WO | claimed |
| EP-0254623-B1 | AMINOALKYLTHIO TRIAZOLOPYRIDINE OR TRIAZOLOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS CONTAINING THEM, PARTICULARLY USEFUL AS ANTALGICS | LABORATOIRES UPSA (FR) | 1993-06-09 | — | — | EP | claimed |
| EP-0539180-A1 | Antiviral agents | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1993-04-28 | — | — | EP | claimed |
| US-4868299-A | Antibacterially active pyrido-benzothiazine derivatives with long-term action | MEDIOLANUM FARMACEUTICI SRL (IT) | 1989-09-19 | — | — | US | claimed |
| EP-0254623-A1 | Aminoalkylthio triazolopyridine or triazoloquinoline derivatives, process for their preparation, medicaments containing them, particularly useful as antalgics | LABORATOIRES UPSA (FR) | 1988-01-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | C5, DDC, SAT1 | ADRB1 2139/4885HTR7 4571/4885HTR1A 4448/4885 |
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | KNTC1, MED1, LEF1 | ADRB1 2085/4885HTR7 4360/4885HTR1A 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.